EMA Authorised: Osenvelt (denosumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA has authorised Osenvelt (denosumab) for Giant Cell Tumor of Bone and related bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone
• Neoplasms Bone Tissue

Drugs mentioned

• Osenvelt (denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 11/08/2026